Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsForexCryptocurrenciesCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

AstraZeneca shares rise on early U.S. approval for leukaemia drug

share with twitter share with LinkedIn share with facebook
share via e-mail
11/22/2019 | 10:37am EST
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York, United States

AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie.

AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukaemia in adults.

The drug was approved under a new speedy review programme in collaboration with drug watchdogs in Canada and Australia, and was also approved to treat small lymphocytic lymphoma, a similar disease.

That will pit the AstraZeneca drug against AbbVie and Johnson & Johnson's established CLL treatment Imbruvica.

The FDA's green light, which analysts at brokerage Bryan Garnier said came at record speed, adds momentum to Astra's growing cancer drug business with brands including Tagrisso and Imfinzi.

"Physicians are used to Imbruvica and we do not expect a rapid and massive shift towards Calquence but we do see it progressively taking market share from the leader," Bryan Garnier analysts said, adding that FDA tests had showed Calquence performed well in terms of side effects.

Astra shares were up 2.1% at 1415 GMT, outperforming a 0.7% gain in the STOXX Europe 600 Health Care index.

Astra shares have risen 28% this year, boosted by revenue growth from new drugs.

Average analyst forecasts point to 2024 Calquence sales of almost $1.5 billion, up from a projected $160 million this year, according to Refinitiv data.

Abbvie and J&J chalked up 2018 Imbruvica revenues of $3.6 billion and $2.6 billion, respectively.

Calquence had previously been approved for the relatively smaller group of mantle cell lymphoma (MCL) patients that had received prior therapy.

(Reporting by Ludwig Burger; Editing by Susan Fenton)

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. -1.36% 94.05 Delayed Quote.6.22%
ASTRAZENECA PLC 1.14% 7377 Delayed Quote.-3.02%
ROCHE HOLDING AG 0.79% 343.3 Delayed Quote.8.47%
SHARE PLC 17.42% 34.051 Delayed Quote.14.29%
STOXX EUROPE 600 0.34% 431.98 Delayed Quote.3.66%
STOXX EUROPE 600 NR 0.34% 933.5 Delayed Quote.3.80%
THE 600 GROUP PLC 0.00% 14.1 Delayed Quote.-4.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
12:14aSUZUKI MOTOR : Partial amendments to “Reference for FY2019 (The 154th Fiscal Year) First Nine Months” and “FY2019 Financial Presentation (Third Quarter)”
12:12aHSBC : sets new cost cutting, earnings targets after 2019 profit falls 33%
12:11aSingapore builders seek force majeure advice as coronavirus causes labour crunch
12:01aInnospec Reports Fourth Quarter and Full Year 2019 Financial Results
12:01aGROVE VENTURES : Closes Second Fund with $120 Million in Commitments
02/17HSBC : 2019 Net Profit Plunges 53%
02/17DOHA BANK : Achieves Net Profit of QR. 754 Million for 2019
02/17CAPITALAND MALL TRUST : Proposed Merger Of Capitaland Mall Trust And Capitaland Commercial Trust (Dealings Disclosure)
02/17HANG SENG BANK : Net Profit Inched Higher in 2019
02/17Oil prices fall as market weighs coronavirus demand impact
Latest news "Companies"